Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer

References

• Nowell PC . The clonal evolution of tumor cell populations . Science194 ( 4260 ), 23 – 28 ( 1976 ).
   PubMed Web of Science ®Google Scholar
• Baylin SB , OhmJE . Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nat. Rev. Cancer6 ( 2 ), 107 – 116 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Esteller M . Epigenetics in cancer . N. Engl. J. Med.358 ( 11 ), 1148 – 1159 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Dawson MA , KouzaridesT . Cancer epigenetics: from mechanism to therapy . Cell150 ( 1 ), 12 – 27 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Clermont PL , CreaF , ChiangYTet al. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer . Clin. Epigenet.8 , 16 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Crea F , Di PaoloA , LiuHHet al. Polycomb genes are associated with response to imatinib in chronic myeloid leukemia . Epigenomics7 ( 5 ), 757 – 765 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Richly H , AloiaL , Di CroceL . Roles of the Polycomb group proteins in stem cells and cancer . Cell Death Dis.2 , e204 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Crea F , HurtEM , MathewsLAet al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer . Mol. Cancer10 , 40 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Crea F , FornaroL , BocciGet al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis . Cancer Metastasis Rev.31 ( 3–4 ), 753 – 761 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Simon JA , KingstonRE . Mechanisms of Polycomb gene silencing: knowns and unknowns . Nat. Rev. Mol. Cell Biol.10 ( 10 ), 697 – 708 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Simon JA , KingstonRE . Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put . Mol. Cell49 ( 5 ), 808 – 824 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Varambally S , DhanasekaranSM , ZhouMet al. The Polycomb group protein EZH2 is involved in progression of prostate cancer . Nature419 ( 6907 ), 624 – 629 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Crea F , HurtEM , FarrarWL . Clinical significance of Polycomb gene expression in brain tumors . Mol. Cancer9 , 265 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Crea F , FornaroL , PaolicchiEet al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients . Ann. Oncol.23 ( 5 ), 1207 – 1213 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Paolicchi E , PacettiP , GiovannettiEet al. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma . Oncol. Lett.6 ( 5 ), 1487 – 1491 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fornaro L , FavianaP , De GregorioVet al. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer . BMC Cancer15 , 874 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Avan A , CreaF , PaolicchiEet al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells . Mol. Cancer Ther.11 ( 8 ), 1735 – 1746 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kim KH , RobertsCW . Targeting EZH2 in cancer . Nat. Med.22 ( 2 ), 128 – 134 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Morera L , LubbertM , JungM . Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy . Clin. Epigenetics8 , 57 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Clermont PL , LinD , CreaFet al. Polycomb-mediated silencing in neuroendocrine prostate cancer . Clin. Epigenetics7 , 40 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Sato T , KanedaA , TsujiSet al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer . Sci. Rep.3 , 1911 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tan J , YangX , ZhuangLet al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells . Genes Dev.21 ( 9 ), 1050 – 1063 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Szasz AM , LanczkyA , NagyAet al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients . Oncotarget7 ( 31 ), 49322 – 49333 ( 2016 ).
   PubMedGoogle Scholar
• Gyorffy B , LanczkyA , EklundACet al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients . Breast Cancer Res. Treat.123 ( 3 ), 725 – 731 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Li Q , BirkbakNJ , GyorffyB , SzallasiZ , EklundAC . Jetset: selecting the optimal microarray probe set to represent a gene . BMC Bioinformatics12 , 474 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mihaly Z , KormosM , LanczkyAet al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer . Breast Cancer Res. Treat.140 ( 2 ), 219 – 232 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N . Comprehensive molecular characterization of gastric adenocarcinoma . Nature513 ( 7517 ), 202 – 209 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Du XY , LiuX , WangZJ , WangYY . SLPI promotes the gastric cancer growth and metastasis by regulating the expression of P53, Bcl-2 and Caspase-8 . Eur. Rev. Med. Pharmacol. Sci.21 ( 7 ), 1495 – 1501 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Pereira B , ChinSF , RuedaOMet al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes . Nat. Commun.7 , 11479 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Guo DQ , ZhangH , TanSJ , GuYC . Nifedipine promotes the proliferation and migration of breast cancer cells . PLoS ONE9 ( 12 ), e113649 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Xu LZ , LiSS , ZhouWet al. p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA . Oncogene36 ( 3 ), 304 – 317 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Moses H , Barcellos-HoffMH . TGF-beta biology in mammary development and breast cancer . Cold Spring Harb. Perspect. Biol.3 ( 1 ), a003277 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kerppola TK . Polycomb group complexes – many combinations, many functions . Trends Cell Biol.19 ( 12 ), 692 – 704 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Morey L , HelinK . Polycomb group protein-mediated repression of transcription . Trends Biochem. Sci.35 ( 6 ), 323 – 332 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Miranda TB , CortezCC , YooCBet al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation . Mol. Cancer Ther.8 ( 6 ), 1579 – 1588 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kaneko S , BonasioR , Saldana-MeyerRet al. Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin . Mol. Cell53 ( 2 ), 290 – 300 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kaneko S , LiG , SonJet al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA . Genes Dev.24 ( 23 ), 2615 – 2620 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wan J , ZhanJ , LiSet al. PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression . Nucleic Acids Res.43 ( 7 ), 3591 – 3604 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yan J , LiB , LinBet al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma . Blood128 ( 7 ), 948 – 958 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Gao SB , ZhengQF , XuBet al. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma . Mol. Cancer Res.12 ( 10 ), 1388 – 1397 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wang P , LiZ , LiuH , ZhouD , FuA , ZhangE . MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2 . Biochem. Biophys. Res. Commun.479 ( 1 ), 91 – 96 ( 2016 ).
   PubMed Web of Science ®Google Scholar